< 1 minute read
Nov. 26, 2021
Vimseltinib: An Oral CSF1R Kinase Inhibitor
vimseltinib
selective CSF1R kinase inhibitor oral, 30 mg BIW, phase III, cancer from structure-based design Molecular Cancer Therapeutics Deciphera Pharmaceuticals
Loading...
selective CSF1R kinase inhibitor oral, 30 mg BIW, phase III, cancer from structure-based design Molecular Cancer Therapeutics Deciphera Pharmaceuticals